Takeda Pharmaceutical is sending mixed signals. Short sellers are retreating. But the options market just printed its most extreme bearish reading in 52 weeks.
The divergence is the story.
The put/call ratio closed at 2.35 on May 20 — the highest in a full year. That's 4.06 standard deviations above the 20-day mean of 0.36. For context, the PCR was below 0.20 for most of April. It has now jumped more than tenfold in under a month.
This is not a gradual drift. It's a sharp, sudden demand for downside protection. The options market is pricing in risk that the equity market has not yet fully reflected.
The lending data tells the opposite story. Short interest peaked at 5.2M shares on May 12. It has since fallen to 4.46M shares — a 14% drop in eight days.
Borrow cost sits at 0.70% — low by any standard. Availability is at 201%, meaning there are roughly two shares available to lend for every one currently borrowed. The lending pool is not tight. There is no short-squeeze pressure building here.
This directly contradicts the options signal. Short sellers are covering. Options traders are buying puts. One of these camps is wrong.
Note: This is a significant change from the May 13 picture, when borrow cost had spiked above 3% and availability was running at over 9,000%. Both metrics have normalised sharply since then — CTB is down roughly 77% from that peak, and availability has tightened considerably as short interest rebuilt and then partially unwound.
The holder base shows no panic. BlackRock added 1.83M shares in its most recent filing. Capital Research added 3.66M shares. These are large, deliberate builds — not the footprint of institutions heading for the exit.
The ORTEX short score sits at 40.3. That's mid-range. The short score has been largely stable over the past two weeks, drifting between 39.6 and 43.6. Nothing extreme in either direction.
The next earnings event is scheduled for July 30. The last print saw the stock move +1.3% on the day and +1.6% over five days — a muted response. But the current PCR reading, sustained across three consecutive sessions at the 52-week high, suggests options traders are positioning for something larger this time. Whether the shorts who just covered agree is the key question.
Data summary
See the live data behind this article on ORTEX.
Open TAK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
